Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that PARI plays potential oncogenic roles and functions as a transcriptional target and effector of FOXM1 in GC development.
|
29805304 |
2018 |
Orchitis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These human aromatase-expressing transgenic mice (<i>AROM+</i>) develop testicular inflammation and impaired spermatogenesis during aging, and the present data show that this is associated with strikingly elevated <i>Nlrp3</i> expression in the testes compared to WT controls.
|
29907661 |
2018 |
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of PARI by RNA inference decreased cell proliferation, migration, and invasion of GC cells <i>in vitro</i>, as well as reduced the xenograft tumor growth and lung metastasis formation <i>in vivo</i>.
|
29805304 |
2018 |
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that PARI plays potential oncogenic roles and functions as a transcriptional target and effector of FOXM1 in GC development.
|
29805304 |
2018 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.
|
30949905 |
2019 |
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.
|
30949905 |
2019 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
Respiratory Distress Syndrome, Newborn
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cut-off values of FLV ≤27.2 cm<sup>3</sup> and PARI ≥0.77 predicted the subsequent development of RDS.
|
28969484 |
2019 |
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
|
30949905 |
2019 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analyses suggested that upregulation of PARPBP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC.
|
30949905 |
2019 |
Idiopathic Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
|
30698487 |
2020 |